Redhill Biopharma (RDHL) PT Raised to $30 at Roth Capital

Roth Capital analyst Scott Henry reiterated a Buy rating and boosted his price target on Redhill Biopharma (NASDAQ: RDHL) to $30.00 (from $27.50) after the company announced positive top line data this morning for RHB-105 to treat H. pylori. The eradication rate for RHB-105 of 89.4% easily topped historical controls of 70% (p<0.001).

"We upped our approval probability for RHB-105 to 75% from 50% based on this event, which increased our price target on RDHL shares to $30 (from $27.50)," Henry said.

For an analyst ratings summary and ratings history on Redhill Biopharma click here. For more ratings news on Redhill Biopharma click here.

Shares of Redhill Biopharma closed at $16.46 yesterday.

You May Also Be Interested In

• Kepler Cheuvreux Upgrades Entain PLC (ENT:LN) (GMVHF) to Buy
• USA Compression Partners LP (USAC) PT Raised to $31 at RBC Capital
• Comstock Resources (CRK) PT Raised to $20 at Mizuho